Subject(s)
Community-Acquired Infections/diagnosis , Endocarditis/diagnosis , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/diagnosis , Anti-Bacterial Agents/pharmacology , Body Fluids/microbiology , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Daptomycin/administration & dosage , Echocardiography, Transesophageal , Endocarditis/drug therapy , Endocarditis/microbiology , Female , Humans , Italy , Methicillin-Resistant Staphylococcus aureus/genetics , Middle Aged , Pericardiocentesis , Rifampin/administration & dosage , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Treatment OutcomeABSTRACT
Anti-tumour necrosis factor (TNF)-alpha treatments are immunosuppressant and represent an important risk factor for developing infections. We report a case of Salmonella paratyphi bacteraemia associated with soft tissue infection in a patient who used infliximab and had recently travelled to India. This case report provides supporting evidence, essentially based only on case reports, that patients receiving anti-TNF-alpha treatments have an increased susceptibility to Salmonella infections, which may develop at unusual and disseminated sites. We emphasize the importance of appropriate counselling of patients undergoing anti-TNF treatment and travelling to areas in which Salmonellae are endemic, as well as the importance of advice to these patients concerning food hygiene.
